BioCentury
ARTICLE | Company News

BeiGene enters U.S. market with first approval for in-house pipeline

November 15, 2019 11:43 PM UTC
Updated on Nov 16, 2019 at 1:57 AM UTC

With its first approval for an internally developed drug, BeiGene faces tough competition as it seeks to carve out a niche for Brukinsa. But the third-to-market Btk inhibitor could have an edge on efficacy without added toxicity and will have an experienced leader behind the U.S. commercial launch.

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) gained $1.47 to $198.25 on NASDAQ and HK$7.80 to HK$125.20 on the Hong Kong stock exchange Friday, after FDA granted Brukinsa zanubrutinib accelerated approval for mantle cell lymphoma (MCL) patients treated with at least one prior therapy...

BCIQ Company Profiles

BeiGene Ltd.

BCIQ Target Profiles

Bruton's tyrosine kinase (Btk)